Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology

- Tocchetti, Carlo Gabriele, Farmakis, Dimitrios, Plummer, Chris, Gulati, Geeta, Ramalingam, Sivatharshini, Cardinale, Daniela, Brezden-Masley, Christine, Iakobishvili, Zaza, Thavendiranathan, Paaladinesh, Santoro, Ciro, Bergler-Klein, Jutta, Keramida, Kalliopi, Koop, Yvonne, de Boer, Rudolf A., Maack, C, Lutgens, E, Rassaf, T, Fradley, MG, Moslehi, J, Yang, EH, De Keulenaer, G, Ameri, P, Bax, J, Andres, Maria Sol, Neilan, TG, Herrmann, J, Mbakwem, AC, Mirabel, M, Skouri, H, Hirsch, E, Cohen-Solal, A, Sverdlov, Aaron L., van der Meer, P, Asteggiano, R, Couch, Liam S., Barac, A, Ky, B, Lenihan, D, Dent, S, Seferovic, P, Coats, AJS, Metra, M, Rosano, G, Suter, T, Lopez-Fernandez, T, Formisano, Luigi, Lyon, AR, Ciardiello, Fortunato, Pane, Fabrizio, Au, Lewis, Emmerich, Max

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

- Lyon, Alexander R., Dent, Susan, Stanway, Susannah, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo G., Moslehi, Javid J., Groarke, John D., Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S., von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendiranathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G., Sverdlov, Aaron L.